iQure Pharma

Executive Summary

iQure Pharma is a clinical-stage biotechnology company pioneering first-in-class small molecule therapies for central nervous system (CNS) disorders. The company's innovative approach targets astrocyte biology to restore glutamate homeostasis, breaking the cycle of excitotoxicity that drives neuronal damage. Founded in 2018 and based in Cambridge, MA, iQure is addressing significant unmet needs in CNS diseases, starting with treatment-resistant epilepsy. Its lead asset, iQ-007, is an orally available small molecule currently in Phase 1 development, designed to modulate glutamate levels and provide a novel mechanism of action for patients who do not respond to existing antiseizure medications. Treatment-resistant epilepsy affects approximately one-third of epilepsy patients, representing a large market opportunity with high medical need. iQ-007's unique astrocyte-targeting mechanism offers potential for differentiated efficacy and tolerability. The Phase 1 trial is evaluating safety, tolerability, and pharmacokinetics in healthy volunteers, with plans to advance into proof-of-concept studies in patients. If successful, iQ-007 could become a transformative therapy for refractory epilepsy and potentially expand into other CNS disorders characterized by glutamate dysregulation, such as Alzheimer's disease and traumatic brain injury. iQure Pharma's strong scientific foundation and clear clinical path position it as a compelling player in the CNS space.

Upcoming Catalysts (preview)

• Q2 2027Phase 1 Clinical Data Readout for iQ-007 in Treatment-Resistant Epilepsy60% success